NCT01345019 2022-11-08
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma
Amgen
Phase 3 Completed
Clinical Trials
10 trialsNCT00330759 2022-11-07
Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.
Amgen
Phase 3 Completed
NCT00622505 2021-05-26
Z-MARK
Novartis
Phase 4 Completed
NCT00424983 2020-12-21
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
Novartis
Phase 1 Completed
NCT02739594 2016-07-22
COMPARE
Hoffmann-La Roche
Phase 3 Terminated
NCT00242528 2015-04-14
Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma.
Novartis
Phase 4 Withdrawn
NCT00741377 2013-02-18
A Study to Assess BHQ880 in Combination With Zoledronic Acid in Relapsed or Refractory Myeloma Patients
Novartis
Phase 1 Completed
NCT00171925 2012-04-11
Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage I
Novartis
Phase 3 Terminated
NCT00029224 2012-02-01
Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
Novartis
Phase 4 Completed
NCT00104104 2011-06-29
A Multiple Myeloma Trial in Patients With Bone Metastases
Novartis
Phase 4 Completed